FDA approves Roche blood test for diagnosing Alzheimer’s disease, company says

The Food and Drug Administration has approved a new blood test intended to help diagnose Alzheimer’s disease, Roche announced, describing it as the fourth such blood test authorized in less than two years.

Roche said the FDA approval covers its Elecsys Phospho-Tau blood test. The company said the authorization is designed for diagnosing Alzheimer’s disease, positioning the test as an alternative to diagnostic approaches that may rely more heavily on other clinical and laboratory assessments.

According to the report, the FDA’s decision comes after a period in which multiple blood-based Alzheimer’s tests have received authorization quickly. Roche said the Elecsys Phospho-Tau test represents the fourth approval of a blood test for Alzheimer’s diagnosis within that two-year window.

The shift toward blood tests matters for how clinicians evaluate patients and for how health systems plan for access and costs. Blood tests can be administered through routine laboratory workflows, which may affect referral patterns, turnaround times, and the overall burden of evaluation compared with diagnostics that require specialized procedures or imaging.

Roche’s announcement also raises practical questions that typically accompany new diagnostic authorizations, including how broadly the test will be adopted in clinical settings, what reimbursement arrangements may be required, and what safeguards and clinical guidance will be developed for appropriate use.

If additional FDA documentation or labeling details become available, they will be central to understanding the test’s intended use, any limitations described by the agency, and the next steps for regulators, clinicians, and payers as blood testing expands across Alzheimer’s care pathways.